AAAAAA

   
Results: 1-25 | 26-28
Results: 1-25/28
The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process
Authors: Sjogren, M Davidsson, P Gottfries, J Vanderstichele, H Edman, A Vanmechelen, E Wallin, A Blennow, K
Citation: M. Sjogren et al., The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process, DEMENT G C, 12(4), 2001, pp. 257-264
Transient increase in total tau but not phospho-tau in human cerebrospinalfluid after acute stroke
Authors: Hesse, C Rosengren, L Andreasen, N Davidsson, P Vanderstichele, H Vanmechelen, E Blennow, K
Citation: C. Hesse et al., Transient increase in total tau but not phospho-tau in human cerebrospinalfluid after acute stroke, NEUROSCI L, 297(3), 2001, pp. 187-190
An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-alpha
Authors: Hemmer, K Fransen, L Vanderstichele, H Vanmechelen, E Heuschling, P
Citation: K. Hemmer et al., An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-alpha, NEUROCHEM I, 38(7), 2001, pp. 557-565
Cerebrospinal fluid tau and beta-amyloid((I-42)) in dementia disorders
Authors: Vanmechelen, E Vanderstichele, H Hulstaert, F Andreasen, N Minthon, L Winblad, B Davidsson, P Blennow, K
Citation: E. Vanmechelen et al., Cerebrospinal fluid tau and beta-amyloid((I-42)) in dementia disorders, MECH AGE D, 122(16), 2001, pp. 2005-2011
Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease
Authors: Andreasen, N Gottfries, J Vanmechelen, E Vanderstichele, H Davidsson, P Blennow, K Rosengren, L Blennow, K
Citation: N. Andreasen et al., Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease, J NE NE PSY, 71(4), 2001, pp. 557-558
Both total and phosphorylated tau are increased in Alzheimer's disease
Authors: Sjogren, M Davidsson, P Tullberg, M Minthon, L Wallin, A Wikkelso, C Granerus, AK Vanderstichele, H Vanmechelen, E Blennow, K
Citation: M. Sjogren et al., Both total and phosphorylated tau are increased in Alzheimer's disease, J NE NE PSY, 70(5), 2001, pp. 624-630
The discrepancy between presenilin subcellular localization and gamma-secretase processing of amyloid precursor protein
Authors: Cupers, P Bentahir, M Craessaerts, K Orlans, I Vanderstichele, H Saftig, P De Strooper, B Annaert, W
Citation: P. Cupers et al., The discrepancy between presenilin subcellular localization and gamma-secretase processing of amyloid precursor protein, J CELL BIOL, 154(4), 2001, pp. 731-740
Tau and A beta 42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values
Authors: Sjogren, M Vanderstichele, H Agren, H Zachrisson, O Edsbagge, M Wikkelso, C Skoog, I Wallin, A Wahlund, LO Marcusson, J Nagga, K Andreasen, N Davidsson, P Vanmechelen, E Blennow, K
Citation: M. Sjogren et al., Tau and A beta 42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values, CLIN CHEM, 47(10), 2001, pp. 1776-1781
Evaluation of CSF-tau and CSF-A beta 42 as diagnostic markers for Alzheimer disease in clinical practice
Authors: Andreasen, N Minthon, L Davidsson, P Vanmechelen, E Vanderstichele, H Winblad, B Blennow, K
Citation: N. Andreasen et al., Evaluation of CSF-tau and CSF-A beta 42 as diagnostic markers for Alzheimer disease in clinical practice, ARCH NEUROL, 58(3), 2001, pp. 373-379
CSF-phospho-tau (181P) as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies
Authors: Vanmechelen, E Van Kerschaver, E Blennow, K De Deyn, PP Galasko, D Parnetti, L Sindic, CJM Arai, H Riemenschneider, M Hampel, H Pottel, H Valgaeren, A Hulstaert, F Vanderstichele, H
Citation: E. Vanmechelen et al., CSF-phospho-tau (181P) as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies, ALZHEIMER'S DISEASE, 2001, pp. 285-291
Standardization of measurement of beta-amyloid((1-42)) in cerebrospinal fluid and plasma
Authors: Vanderstichele, H Van Kerschaver, E Hesse, C Davidsson, P Buyse, MA Andreasen, N Minthon, L Wallin, A Blennow, K Vanmechelen, E
Citation: H. Vanderstichele et al., Standardization of measurement of beta-amyloid((1-42)) in cerebrospinal fluid and plasma, AMYLOID, 7(4), 2000, pp. 245-258
Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease
Authors: Kumar-Singh, S De Jonghe, C Cruts, M Kleinert, R Wang, R Mercken, M De Strooper, B Vanderstichele, H Lofgren, A Vanderhoeven, I Backhovens, H Vanmechelen, E Kroisel, PM Van Broeckhoven, C
Citation: S. Kumar-singh et al., Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease, HUM MOL GEN, 9(18), 2000, pp. 2589-2598
Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies
Authors: Van Gool, SW Van Kerschaver, E Brock, P Pottel, H Hulstaert, F Vanmechelen, E Uyttebroeck, A Van De Voorde, A Vanderstichele, H
Citation: Sw. Van Gool et al., Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies, LEUKEMIA, 14(12), 2000, pp. 2076-2084
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization
Authors: Vanmechelen, E Vanderstichele, H Davidsson, P Van Kerschaver, E Van Der Perre, B Sjogren, M Andreasen, N Blennow, K
Citation: E. Vanmechelen et al., Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization, NEUROSCI L, 285(1), 2000, pp. 49-52
Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline
Authors: Riemenschneider, M Schmolke, M Lautenschlager, N Guder, WG Vanderstichele, H Vanmechelen, E Kurz, A
Citation: M. Riemenschneider et al., Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline, NEUROSCI L, 284(1-2), 2000, pp. 85-88
CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging
Authors: Sjogren, M Minthon, L Davidsson, P Granerus, AK Clarberg, A Vanderstichele, H Vanmechelen, E Wallin, A Blennow, K
Citation: M. Sjogren et al., CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging, J NEURAL TR, 107(5), 2000, pp. 563-579
Aging increased amyloid peptide and caused amyloid plaques in brain of oldAPP/V717I transgenic mice by a different mechanism than mutant presenilin1
Authors: Dewachter, I Van Dorpe, J Smeijers, L Gilis, M Kuiperi, C Laenen, I Caluwaerts, N Moechars, D Checler, DR Vanderstichele, H Van Leuven, F
Citation: I. Dewachter et al., Aging increased amyloid peptide and caused amyloid plaques in brain of oldAPP/V717I transgenic mice by a different mechanism than mutant presenilin1, J NEUROSC, 20(17), 2000, pp. 6452-6458
Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons
Authors: Van Dorpe, J Smeijers, L Dewachter, I Nuyens, D Spittaels, K Van den Haute, C Mercken, M Moechars, D Laenen, I Kuiperi, C Bruynseels, K Tesseur, I Loos, R Vanderstichele, H Checler, F Sciot, R Van Leuven, F
Citation: J. Van Dorpe et al., Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons, AM J PATH, 157(4), 2000, pp. 1283-1298
Evidence that A beta 42 plasma levels in presenilin-1 mutation carriers donot allow for prediction of their clinical phenotype
Authors: De Jonghe, C Cras, P Vanderstichele, H Cruts, M Vanderhoeven, I Smouts, I Vanmechelen, E Martin, JJ Hendriks, L Van Broeckhoven, C
Citation: C. De Jonghe et al., Evidence that A beta 42 plasma levels in presenilin-1 mutation carriers donot allow for prediction of their clinical phenotype, NEUROBIOL D, 6(4), 1999, pp. 280-287
Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased A beta 42 secretion
Authors: De Jonghe, C Cruts, M Rogaeva, EA Tysoe, C Singleton, A Vanderstichele, H Meschino, W Dermaut, D Vanderhoeven, I Backhovens, H Vanmechelen, E Morris, CM Hardy, J Rubinsztein, DC St George-Hyslop, PH Van Broeckhoven, C
Citation: C. De Jonghe et al., Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased A beta 42 secretion, HUM MOL GEN, 8(8), 1999, pp. 1529-1540
Cerebrospinal fluid tau and A beta 42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
Authors: Andreasen, N Minthon, L Vanmechelen, E Vanderstichele, H Davidsson, P Winblad, B Blennow, K
Citation: N. Andreasen et al., Cerebrospinal fluid tau and A beta 42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment, NEUROSCI L, 273(1), 1999, pp. 5-8
Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
Authors: Andreasen, N Minthon, L Clarberg, A Davidsson, P Gottfries, J Vanmechelen, E Vanderstichele, H Winblad, B Blennow, K
Citation: N. Andreasen et al., Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample, NEUROLOGY, 53(7), 1999, pp. 1488-1494
Improved discrimination of AD patients using beta-amyloid((1-42)) and tau levels in CSF
Authors: Hulstaert, F Blennow, K Ivanoiu, A Schoonderwaldt, HC Riemenschneider, M De Deyn, PP Bancher, C Cras, P Wiltfang, J Mehta, PD Iqbal, K Pottel, H Vanmechelen, E Vanderstichele, H
Citation: F. Hulstaert et al., Improved discrimination of AD patients using beta-amyloid((1-42)) and tau levels in CSF, NEUROLOGY, 52(8), 1999, pp. 1555-1562
Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency
Authors: Herreman, A Hartmann, D Annaert, W Saftig, P Craessaerts, K Serneels, L Umans, L Schrijvers, V Checler, F Vanderstichele, H Baekelandt, V Dressel, R Cupers, P Huylebroeck, D Zwijsen, A Van Leuven, F De Strooper, B
Citation: A. Herreman et al., Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency, P NAS US, 96(21), 1999, pp. 11872-11877
Cerebrospinal fluid beta-amyloid((1-42)) in Alzheimer disease - Differences between early- and late-onset Alzheimer disease and stability during the course of disease
Authors: Andreasen, N Hesse, C Davidsson, P Minthon, L Wallin, A Winblad, B Vanderstichele, H Vanmechelen, E Blennow, K
Citation: N. Andreasen et al., Cerebrospinal fluid beta-amyloid((1-42)) in Alzheimer disease - Differences between early- and late-onset Alzheimer disease and stability during the course of disease, ARCH NEUROL, 56(6), 1999, pp. 673-680
Risultati: 1-25 | 26-28